Traws Pharma Files 8-K on Financials

Ticker: TRAW · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1130598

Traws Pharma, Inc. 8-K Filing Summary
FieldDetail
CompanyTraws Pharma, Inc. (TRAW)
Form Type8-K
Filed DateNov 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, corporate-action

TL;DR

Traws Pharma dropped an 8-K on Nov 13th covering financials. Check it out.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company is incorporated in Delaware and its principal business address is in Newtown, PA.

Why It Matters

This 8-K filing provides an update on Traws Pharma's financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial results and does not appear to contain any significant new risks or negative developments.

Key Players & Entities

  • Traws Pharma, Inc. (company) — Registrant
  • Onconova Therapeutics, Inc. (company) — Former company name
  • November 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Newtown, PA (location) — Business address

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Traws Pharma, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements.

What was Traws Pharma, Inc. formerly known as?

Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on November 13, 2025.

In which state is Traws Pharma, Inc. incorporated?

Traws Pharma, Inc. is incorporated in Delaware.

What is the business address of Traws Pharma, Inc.?

The business address of Traws Pharma, Inc. is 12 Penns Trail, Newtown, PA 18940.

Filing Stats: 853 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-11-13 07:01:02

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K (this "Current Report") regarding the Earnings Release is incorporated by reference into this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 13, 2025, Traws Pharma, Inc. (the "Company") issued a press release (the "Earnings Release") announcing its financial results for the quarter ended September 30, 2025, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference. Additionally, on November 13, 2025, the Company began using a new corporate presentation. A copy of that corporate presentation is furnished as Exhibit 99.2 hereto and incorporated herein by reference. The presentation will also be posted to the Company's website. The information set forth under Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

Forward-Looking Statements This Current Report, including Exhibits 99.1 and 99.2, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes," "will" and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements in

Forward-looking statements in this Current Report, including Exhibits 99.1 and 99.2, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company's business and the accuracy of the forward-looking statements contained herein.

01

Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 13, 2025. 99.2 Investor Presentation, dated November 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 13, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.